1. Home
  2. ROIV vs KNX Comparison

ROIV vs KNX Comparison

Compare ROIV & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$28.81

Market Cap

20.7B

Sector

Health Care

ML Signal

HOLD

Logo Knight-Swift Transportation Holdings Inc.

KNX

Knight-Swift Transportation Holdings Inc.

HOLD

Current Price

$52.85

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
KNX
Founded
2014
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
20.7B
7.0B
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
ROIV
KNX
Price
$28.81
$52.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
18
Target Price
$27.56
$60.50
AVG Volume (30 Days)
4.7M
2.7M
Earning Date
05-11-2026
04-21-2026
Dividend Yield
N/A
1.39%
EPS Growth
N/A
N/A
EPS
N/A
0.41
Revenue
$29,053,000.00
$7,469,689,000.00
Revenue This Year
N/A
$5.92
Revenue Next Year
$385.85
$7.91
P/E Ratio
N/A
$126.51
Revenue Growth
N/A
0.80
52 Week Low
$8.73
$36.69
52 Week High
$30.33
$64.10

Technical Indicators

Market Signals
Indicator
ROIV
KNX
Relative Strength Index (RSI) 57.64 37.10
Support Level $26.94 $52.67
Resistance Level N/A $54.03
Average True Range (ATR) 1.00 2.57
MACD -0.23 -1.16
Stochastic Oscillator 55.28 9.40

Price Performance

Historical Comparison
ROIV
KNX

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: